Jiangsu Hengrui Medicine (SHA:600276) is considering a a secondary listing in Hong Kong that could raise $2 billion, Bloomberg News reported Thursday, citing people familiar with the matter.
The Shanghai-listed drug manufacturer is now in talks with advisers regarding the IPO, which could take place as early as 2025, the report said, citing the sources.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price (RMB): ¥48.67, Change: ¥-2.0, Percent Change: -3.99%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments